The Felix neuroblastoma PDX harbours the third most common ALK mutation found in neuroblastoma, and it exhibits de novo resistance to the first generation ALK inhibitor, crizotinib, which mirrors that seen clinically for this subgroup of patients. The gene discussed is ALK; the disease is neuroblastoma.